Back Hepatitis B Hepatitis B Topics HBV Treatment

World Health Organization Issues First Hepatitis B Prevention and Treatment Guidelines

The World Health Organization (WHO) released its first-ever guidelines for the prevention, care, and treatment of hepatitis B virus (HBV) infection, a major cause of illness and death worldwide. For treatment, WHO recommends the antivirals tenofovir (Viread) or entecavir (Baraclude), and says that people with liver cirrhosis need treatment most urgently.

alt

Read more:

11. Hepatitis B: Interferon Boosts Cure Rate, Tenofovir Works Long-Term

Compared with hepatitis C and HIV, the hepatitis B treatment field moves slowly, but a number of studies presented in 2014 advanced knowledge about how best to treat chronic hepatitis B virus (HBV) with existing therapies and offered some promising agents in the pipeline. 

alt

Read more:

AASLD 2014: Entecavir and Tenofovir Work Well for People with Resistant Hepatitis B Virus

A combination of entecavir plus tenofovir effectively suppressed hepatitis B virus (HBV) in people with resistance to other antivirals, according to results from the ENTEBE study presented at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting last month in Boston. Another study, however, showed that for some resistant patients, tenofovir worked equally well on its own.

alt

Read more:

AASLD 2014: Experimental siRNA Therapy Lowers HBsAg Levels in Hepatitis B Patients

ARC-520, a novel therapy using short interfering RNA, appeared safe and was associated with a reduction in hepatitis B surface antigen levels in chronic hepatitis B patients taking entecavir, according to Phase 2a study results reported at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting last month in Boston.

alt

Read more:

Coverage of the 2014 AASLD Liver Meeting

HIVandHepatitis.com coverage of the 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2014) in Boston, November 7-11, 2014.

Conference highlights include new interferon-free therapy for hepatitis C -- including options for people with cirrhosis, and liver transplant recipients -- treatment for hepatitis B, and prevention and management of advanced liver disease.

Full listing by topic

The Liver Meeting website

12/2/14

alt